25 / 46
QoL con Radium 223 (ALSYMPCA)
Mean changes in utility and FACT-P total scores from baseline over time indicate that higher QOL observed with
radium-223 patients was a direct consequence of a slower rate of decline in QOL with radium-223 versus placebo.
Nilsson S, et al.
Ann Oncol.
2016;27(5):868-74
EQ-5D UTILITY SCORE
━
Radium-223
━
Placebo
0
-0.05
-0.10
-0.15
-0.20
Change from baseline
0
Week 36
(follow-up visit 1)
Week 44
(follow-up visit 2)
Week 24
Week 16
614
300
220
343
460
307
105
84
131
194
P
= 0.242
P
= 0.828
P
= 0.034
P
= 0.004
━
Ra-223
━
PBO
FACT-P TOTAL SCORE
━
Radium-223
━
Placebo
0
-2
-6
-10
-14
Change from baseline
0
Week 44
(follow-up visit 2)
Week 24
Week 16
614
186
314
407
307
75
120
177
P
= 0.147
P
= 0.112
P
= 0.006
━
Ra-223
━
PBO
-12
-8
-4